TARA Logo

Protara Therapeutics, Inc. (TARA) 

NASDAQ
Market Cap
$47.86M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
730 of 774
Rank in Industry
403 of 432

Largest Insider Buys in Sector

TARA Stock Price History Chart

TARA Stock Performance

About Protara Therapeutics, Inc.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed …

Insider Activity of Protara Therapeutics, Inc.

Over the last 12 months, insiders at Protara Therapeutics, Inc. have bought $0 and sold $1.75M worth of Protara Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Protara Therapeutics, Inc. have bought $2.31M and sold $1.19M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 9,065 shares for transaction amount of $34,810 was made by Shefferman Jesse (CEO and President) on 2022‑08‑11.

List of Insider Buy and Sell Transactions, Protara Therapeutics, Inc.

2024-09-12Sale10 percent owner
126,301
0.6048%
$1.71$215,836+9.25%
2024-09-11Sale10 percent owner
32,600
0.1566%
$1.71$55,880+0.93%
2024-09-10Sale10 percent owner
25,500
0.1264%
$1.77$45,110+9.25%
2024-09-09Sale10 percent owner
36,492
0.1821%
$1.89$69,141+2.72%
2024-07-16Sale10 percent owner
11,396
0.0691%
$2.44$27,828-17.08%
2024-07-11Sale10 percent owner
47,993
0.2866%
$2.40$115,3460.00%
2024-07-10Sale10 percent owner
18,061
0.1036%
$2.31$41,6850.00%
2024-07-09Sale10 percent owner
8,497
0.0467%
$2.21$18,8110.00%
2024-07-01Sale10 percent owner
8,288
0.0437%
$2.12$17,5980.00%
2024-06-28Sale10 percent owner
17,994
0.0927%
$2.07$37,3340.00%
2024-06-27Sale10 percent owner
46,574
0.2613%
$2.26$105,1690.00%
2024-06-25Sale10 percent owner
12,725
0.0665%
$2.26$28,734-5.24%
2024-05-31Sale10 percent owner
5,824
0.0292%
$2.90$16,895-24.73%
2024-05-30Sale10 percent owner
9,230
0.0454%
$2.94$27,113-27.59%
2024-05-22Sale10 percent owner
9,800
0.0481%
$3.02$29,596-29.00%
2024-05-21Sale10 percent owner
33,000
0.1671%
$3.06$100,838-27.30%
2024-05-17Sale10 percent owner
70,885
0.3032%
$3.25$230,326-30.74%
2024-05-10Sale10 percent owner
151,700
0.7648%
$3.11$472,424-26.17%
2024-05-09Sale10 percent owner
30,600
0.1541%
$3.09$94,526-24.66%
2022-12-30Saledirector
15,473
0.1389%
$2.71$41,949-0.75%

Insider Historical Profitability

<0.0001%
Opaleye Management Inc.10 percent owner
45000
0.2181%
$2.321520<0.0001%
O'Leary Brendandirector
1387198
6.7242%
$2.3210
Abingworth LLP10 percent owner
950000
4.605%
$2.3210
Haines Timothy
950000
4.605%
$2.3210
Shefferman JesseCEO and President
879441
4.263%
$2.3210<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Opaleye Management Inc$10.8M13.082.69M0%+$02.38
The Vanguard Group$1.71M2.08427,6120%+$0<0.0001
Boxer Capital, LLC$839,000.001.02209,2270%+$00.02
Ikarian Capital LLC$812,830.000.98202,701+7.44%+$56,288.300.11
Baker Bros Advisors LP$800,681.000.97199,6710%+$00.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.